Edwards Lifesciences Co. (NYSE:EW) Stock Position Raised by Cerity Partners LLC

Cerity Partners LLC lifted its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 3.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 126,834 shares of the medical research company's stock after buying an additional 4,012 shares during the quarter. Cerity Partners LLC's holdings in Edwards Lifesciences were worth $9,207,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Crowley Wealth Management Inc. acquired a new stake in shares of Edwards Lifesciences during the 4th quarter worth $26,000. Millstone Evans Group LLC purchased a new stake in Edwards Lifesciences during the fourth quarter worth approximately $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Edwards Lifesciences in the 4th quarter valued at $30,000. Roble Belko & Company Inc purchased a new position in Edwards Lifesciences in the 4th quarter worth approximately $46,000. Finally, Catalyst Capital Advisors LLC acquired a new stake in Edwards Lifesciences during the 4th quarter valued at $54,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Trading Up 1.3 %

EW traded up $0.93 during trading on Wednesday, reaching $71.69. The company had a trading volume of 878,330 shares, compared to its average volume of 4,616,084. The firm's 50-day simple moving average is $71.27 and its 200 day simple moving average is $70.76. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company has a market cap of $42.14 billion, a price-to-earnings ratio of 10.29, a PEG ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Equities research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Bernard J. Zovighian sold 6,164 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $69.51, for a total transaction of $428,459.64. Following the completion of the sale, the chief executive officer now directly owns 59,083 shares in the company, valued at approximately $4,106,859.33. This trade represents a 9.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the company's stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the transaction, the vice president now owns 23,189 shares in the company, valued at approximately $1,594,475.64. This represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 72,353 shares of company stock worth $5,197,442. Corporate insiders own 1.29% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on EW. Royal Bank of Canada restated an "outperform" rating and set a $85.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Stifel Nicolaus raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and increased their price target for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. Wolfe Research downgraded Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 12th. Piper Sandler boosted their price target on Edwards Lifesciences from $70.00 to $73.00 and gave the company a "neutral" rating in a report on Wednesday, February 12th. Finally, Canaccord Genuity Group increased their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a "hold" rating in a report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $78.55.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.